Guggenheim raises target for Twist Bioscience stock from USD 107.00 to USD 212.00

Published on 10/02/2026 at 17:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Twist Bioscience stock costs EUR 170.15 after EUR 167.75 on October 2, 2026. Revenue rose 23.20 percent year over year to USD 118.38 million.

TWST, US90184D1000, Illustration mit AI erstellt.

Twist Bioscience (ISIN US90184D1000) was trading at EUR 170.15 after the Xetra close on October 2, 2026, while Guggenheim maintained a Buy rating and raised its target from USD 107.00 to USD 212.00 on October 1, 2026, according to Yahoo Finance. The target revision is the clearest fresh valuation signal for the synthetic biology company, but the stock price has already moved well beyond several published estimates.

Guggenheim doubles its target

Guggenheim's move from USD 107.00 to USD 212.00 places the new target above the USD 200.31 52-week high shown for the Nasdaq listing on October 2, 2026. That contrast matters because the target reflects a bullish individual view, while the broader analyst picture remains more cautious.

MarketBeat reported on September 29, 2026, that eight analysts rated Twist Bioscience Buy, two rated it Hold and two rated it Sell, with an average target of USD 103.00. The same report cited a USD 187.87 52-week high at that time, showing how quickly the market level has moved relative to the consensus target.

Revenue growth meets an earnings shortfall

Twist Bioscience generated USD 118.38 million of revenue in fiscal third-quarter 2026, up 23.20 percent from the same period a year earlier, according to MarketBeat. Revenue exceeded the USD 114.55 million estimate, but adjusted earnings per share were a loss of USD 0.56 versus a consensus loss of USD 0.51.

The company also raised fiscal 2026 revenue guidance to USD 456.00 million to USD 457.00 million, as Yahoo Finance reported on September 25, 2026. The figures create a mixed operating picture: revenue growth and higher guidance support the bullish case, while the quarterly loss keeps execution and valuation central to the debate.

AI partnerships sharpen the story

Twist Bioscience announced an agreement with Eli Lilly's TuneLab on September 16, 2026, providing antibody characterization data services and preferred laboratory protocols for the AI-driven drug discovery platform, according to MarketScreener. The partnership gives the target increase a concrete strategic backdrop, but it does not remove the gap between the USD 103.00 average target and the elevated market valuation.

Stock price after the Xetra close

Twist Bioscience was trading at EUR 170.15 at Lang & Schwarz on October 2, 2026 at 5:43 p.m. CEST, plus 1.43 percent versus the prior close of EUR 167.75 on October 1, 2026. At Nasdaq, the stock stood at USD 192.43 at 11:48 a.m. EDT on October 2, 2026, intraday, with a USD 23.30 to USD 200.31 52-week range.